The Alvimedica Cre8™ EVO DES provided superior clinical outcomes vs. Onyx™ DES in the independent SUGAR RCT (TLF at 1 year: 7.2% Cre8™ EVO vs. 10.9% Onyx™; p superiority = 0.030
The only Self-Expanding DES releasing Sirolimus CE marked has proven “top performance” in the ILLUMINA 2years FIM results (SAFETY à 91.9% Freedom from device related MAE; EFFICACY à 93.1% Freedom from TLR and 83.4% Primary Patency rate).
